TY - JOUR
TI - Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia
AU - Filippidou, M.
AU - Avgerinou, G.
AU - Tsipou, H.
AU - Tourkantoni, N.
AU - Katsibardi, K.
AU - Vlachou, A.
AU - Roka, K.
AU - Solomou, E.
AU - Kattamis, A.
JO - British Journal of Haematology
PY - 2020
VL - 190
TODO - 3
SP - e157-e159
PB - Wiley-Blackwell Publishing Ltd
SN - 0007-1048, 1365-2141
TODO - 10.1111/bjh.16766
TODO - cyclosporine;  eltrombopag;  thymocyte antibody;  benzoic acid;  cyclosporine;  eltrombopag;  hydrazine derivative;  immunosuppressive agent;  lymphocyte antibody;  MPL protein, human;  pyrazole derivative;  thrombopoietin receptor, adolescent;  aplastic anemia;  child;  chronic kidney failure;  clinical article;  death;  drug efficacy;  drug response;  drug safety;  drug tolerability;  female;  follow up;  hematopoietic stem cell transplantation;  human;  immunosuppressive treatment;  Letter;  longitudinal study;  low drug dose;  male;  matched unrelated donor;  preschool child;  priority journal;  relapse;  school child;  thrombocytopenia;  treatment duration;  treatment outcome;  virus encephalitis;  aplastic anemia;  clinical trial;  off label drug use, Adolescent;  Anemia, Aplastic;  Antilymphocyte Serum;  Benzoates;  Child;  Child, Preschool;  Cyclosporine;  Female;  Follow-Up Studies;  Humans;  Hydrazines;  Immunosuppressive Agents;  Male;  Off-Label Use;  Pyrazoles;  Receptors, Thrombopoietin;  Treatment Outcome
TODO - null
ER -